Amarin Corporation plc (AMRN)

Market Cap	203.16M
Revenue (ttm)	228.61M
Net Income (ttm)	-82.18M
Shares Out	20.71M
EPS (ttm)	-4.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	171,364
Open	9.40
Previous Close	9.47
Day's Range	9.56 - 9.95
52-Week Range	7.00 - 20.60
Beta	1.39
Analysts	Buy
Price Target	n/a
Earnings Date	Apr 30, 2025

About AMRN

Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. It sells its products principally through wholesalers, selected regional wholesalers, and specialty pharmacy providers. The company has a collaboration...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• IPO Date: Apr 1, 1993
• Employees: 275
• Stock Exchange: NASDAQ
• Ticker Symbol: AMRN
• Website: https://www.amarincorp.com

Financial Performance

In 2024, Amarin Corporation's revenue was $228.61 million, a decrease of -25.51% compared to the previous year's $306.91 million. Losses were -$82.18 million, 39.0% more than in 2023.